Ripple Therapeutics Enters Evaluation and Licensing Agreement with Bausch + Lomb

Ripple Therapeutics与Bausch + Lomb达成评估和许可协议

November 26, 2025

2025年11月26日

Ripple Therapeutics, a clinical-stage company developing polymer-free sustained release drug delivery systems, has entered into an evaluation and licensing option agreement with an affiliate of Bausch + Lomb.

Ripple Therapeutics是一家开发无聚合物缓释药物递送系统的临床阶段公司，已与Bausch + Lomb的附属公司签订了评估和许可选择协议。

Advancing Polymer-Free Controlled Drug Delivery

推进无聚合物控制药物释放

Ripple’s proprietary technology platform is based on the discovery that drugs can be chemically engineered into controlled-release prodrugs without relying on polymers, a component often associated with inflammation. These prodrugs utilize a surface erosion mechanism, enabling zero-order release kinetics, and can be precisely engineered to control both drug dose and duration..

Ripple的专有技术平台基于一项发现，即药物可以被化学工程化为控释前药，而无需依赖常与炎症相关的聚合物。这些前药利用表面侵蚀机制，实现零级释放动力学，并且可以精确设计以控制药物剂量和持续时间。

Agreement Terms and Scope

协议条款与范围

As part of the agreement, Bausch + Lomb will fund early-stage feasibility and preclinical evaluation of a selected target molecule. The company also holds an option to license any of the formulations evaluated under this collaboration. Licensing would be subject to additional financial terms, including milestone payments and royalties..

根据协议，博士伦将资助选定靶点分子的早期可行性及临床前评估。该公司还拥有选择权，可以授权本次合作中评估的任何配方。授权需符合额外的财务条款，包括里程碑付款和特许权使用费。

Leadership Commentary

领导评论

“We’re pleased to partner with Bausch + Lomb and look forward to working with them to develop sustained release implants that will benefit patients with extended duration and improved safety,” said Tom Reeves, President and CEO of Ripple Therapeutics.

“我们很高兴与博士伦合作，并期待与他们一起开发持续释放的植入物，这将使患者受益于更长的持续时间和更高的安全性，”Ripple Therapeutics总裁兼首席执行官汤姆·里夫斯表示。

This collaboration aims to advance sustained-release ophthalmic therapies that may offer improved safety profiles and extended treatment duration.

这项合作旨在推进可能提供更高安全性和更长治疗持续时间的缓释眼科疗法。